MedTrace Logo

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

NCT05813626 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2026-07-10

No results posted yet for this study

Summary

Neoadjuvant chemotherapy plus toripalimab in patients with locoregionally advanced nasopharyngeal carcinoma

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Toripalimab

Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy

DRUG

Gemcitabine (GEM)

3 cycles of intravenous induction gemcitabine (1 g/m2 on days 1 and 8 of each 3-week cycle) once every 3 weeks

DRUG

Cisplatin

3 cycles of intravenous induction cisplatin (80 mg/m2 on day 1) once every 3 weeks.

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-21
Primary Completion
2025-08-15
Completion
2027-10-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05813626 on ClinicalTrials.gov